Athena launches Alzheimer's specific assays
This article was originally published in Clinica
Athena Neurosciences has launched the first disease-specific tests for Alzheimer's. ADmark Assays will allow neurologists to approach diagnosis of the disease by a process of inclusion, rather than exclusion, says Athena. One of a pair of tests partners two biochemical markers, Tau and beta-amyloid (A beta 42) to determine their levels in cerebrospinal fluid. Results can determine Alzheimer's with 95% accuracy in 60% of patients over 60 showing signs of dementia.